| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
RESEARCH |
Department of Gynecology and Obstetrics, University-Clinics Erlangen, Laboratory for Molecular Medicine, Universitaetsstr. 21-23, D-91054 Erlangen, Germany and 1 Buerger-Hospital Frankfurt a.M., Nibelungenallee 37-41, 60318 Frankfurt a.M., Germany
Correspondence should be addressed to P L Strissel; Email: pamela.strissel{at}gyn.imed.uni-erlangen.de
| Abstract |
|---|
|
|
|---|
(ER
) in connection with endometriosis are controversially discussed. From a German population of women, clinical data associated with the disease, including the American Fertility Society (AFS) IIV classification, and non-clinical parameters were evaluated statistically in endometriosis patients (n = 98) and in control women (n = 98) without endometriosis. Using a multivariate statistical analysis, significant associations of endometriosis with dysmenorrhea (P < 0.001) and allergies against medicaments (P = 0.042) were found. A positive trend between first grade family history of endometriosis and allergies against medicaments was also observed, suggesting a genetic relationship. From both collectives, DNA from peripheral blood was analyzed for the frequency of the ER
DNA polymorphisms Xba1 (A/G) and PvuII (T/C) in intron 1 and the ER
exonic DNA polymorphism (G229A) with an amino acid exchange (Gly77Ser) in the transactivation domain. DNA samples from endometriosis lesions and control tissues from the same collectives were also analyzed for the exonic G229A polymorphism. Only homozygote wild-type alleles for the polymorphism G229A were found, making it a rare polymorphism in mid-European individuals. Allele types for the PvuII and Xba1 polymorphisms were analyzed with the observed statistically significant clinical parameters and showed no significant association with endometriosis; however a trend with AFS IV was noted, which could contribute to lesion severity. In conclusion, the analyzed polymorphisms in the ER
do not have a functional role concerning specific clinical parameters associated with endometriosis. | Introduction |
|---|
|
|
|---|
The endometriotic lesion is defined as a steroid hormone-dependent endometrium-like tissue consisting of glands and stroma, which establishes growth outside the uterine cavity. Target tissues and organs include fallopian tubes, ovaries, peritoneum, colon, the recto-vaginal region, bladder, uterus, and more rarely kidney, lung, liver, pancreas, muscle and the central nervous system (Giudice & Kao 2004). Laparoscopy or laparotomy should be performed to confirm and classify the stage of endometriosis according to the American Fertility Society (AFS), where AFS I represents a minimal and AFS IV a severe occurrence. The molecular etiology of endometriosis is still unknown but two main theories exist. As first described by Sampson (1927) based upon retrograde menstruation, endometrial cells adhere, invade and neovascularize the peritoneum resulting in abnormal growth. The metaplasia theory describes an aberrant cellular differentiation process occurring at the site, which results in endometrium-like tissue (Meyer 1919, Gazvani & Templeton 2002). Even though more than 90% of women of reproductive age show at least some degree of retrograde menstruation, it remains unsolved why only some women develop endometriosis. Thus, unidentified factors must be involved that render certain women susceptible to adherence, invasion, growth and persistence of the lesion (Sharpe-Timms 2001). Some of these factors might involve an aberrant immunologic response (Paul Dmowski & Braun 2004), genetic predisposition (Lamb & Nichols 1986, Stefansson et al. 2002, Kashima et al. 2004), or an altered peritoneal cavity or altered eutopic endometrium (Sharpe-Timms et al. 2000, Mahutte et al. 2004).
At present, molecular research has focused on steroid hormone receptors and hormone metabolism and their role in endometriosis. For example, both estrogen and progesterone receptors are present in endometriotic lesions; however conflicting results have shown that the expression levels of estrogen receptor (ER)
and progesterone receptor (PR) are either increased or decreased compared with eutopic endometrium (Lessey et al. 1989, Jones et al. 1995). Importantly, it has been demonstrated in endometrium and endometriotic cysts that estrogens bind preferentially to ER
rather than to ERß (Matsuzaki et al. 2000). Estrogen modulating enzymes in lesions and cell lines showed that, in contrast to normal endometrium of women without endometriosis, expression of CYP19 and 17ß-hydroxysteroid dehydrogenase type 2 (17-HSD2) was present in the lesions and uterine endometrium from patients (Noble et al. 1996, Kitawaki et al. 1999) but, in contrast, expression of 17ß-hydroxysteroid dehydrogenase type 1 (17-HSD1) was deficient (Zeitoun et al. 1998). Both of these enzymatic pathways result in a local cellular accumulation of 17ß estradiol; thus, together with circulating estrogen, a stimulation of growth occurs in endometriotic tissue mediated by the ER, further supporting the view that endometriosis is an estrogen hormone-dependent disease.
A single nucleotide polymorphism (SNP) results from a base substitution mutation. SNPs in protein-coding regions (cSNPs) can be classified as synonymous and non-synonymous, where the latter can result in a missense mutation, with a change of amino acids or a nonsense mutation occuring in a termination codon. In addition, SNPs in promoter regions can result in reduced or increased gene expression, whereas SNPs in introns can result in defective splicing or a change in transcription rate if a regulatory element is mutated. A restriction fragment length polymorphism (RFLP) occurs where cleavage of DNA by a restriction enzyme is due to a nucleotide polymorphism in the restriction recognition site. SNPs occur on average every 1.9 kb in the genome where 1.42 million SNPs have been mapped with over 60 000 being represented within exons and untranslated regions (Marth et al. 2001). Thus, determining DNA sequence variations between individuals could contribute to differences in for example drug sensitivities, disease risk and the clinical course of the disease. There have been a variety of DNA polymorphisms in genes, but only a few have shown an association with endometriosis including genes in the immune system, galactose metabolism, cancer susceptibility genes and in nuclear receptors (Cramer et al. 1996, Baranova et al. 1999, Georgiou et al. 1999, Hsieh et al. 2001, Kitawaki et al. 2001, Chang et al. 2002, Kado et al. 2002, Wieser et al. 2003). Recent studies have postulated that ER
SNPs may influence their action as a modulator of estrogen. Two SNPs, a PvuII restriction site (CAG/CTG) with a T
C base change and an Xba1 restriction site (T/CTAGA) with an A
G base change, are both located in intron 1, 5' of exon 2 (Yaich et al. 1992, Yamada et al. 2002). Interestingly, the PvuII polymorphic site abolishes an activator-protein 4 (AP-4) transcription factor binding site as determined by homology with the DNA consensus sequence (Hu et al. 1990). A TA-dinucleotide repeat polymorphism has also been identified in 5' of exon 1 in the ER
gene (Sano et al. 1995, Becherini et al. 2000). The ER
PvuII polymorphism has been analyzed and reported in over 140 publications involving specific diseases, for example Alzheimers, mineral bone density, breast cancer and endometriosis; however, the Xba1 polymorphism of ER
has been analyzed more rarely (Hill et al. 1989, Parl et al. 1989, Yaich et al. 1992, Georgiou et al. 1999, Becherini et al. 2000, Kitawaki et al. 2001, Brodowska 2003, Kurabayashi et al. 2004, Seko et al. 2004, Wang et al. 2004, Zhang et al. 2004). Both ER
polymorphisms PvuII and Xba1 have demonstrated contradictory results in the literature. Therefore, more analysis is needed in the general population to ultimately determine their involvement with diseases, especially with endometriosis.
In the present investigation, following clinical data evaluation of a German population of women with endometriosis and of control individuals, we first determined statistically significant associations with disease, clinical history and lifestyle characteristics. Secondly, the incidence of different genetic polymorphisms of ER
in 98 endometriosis patients and 98 control individuals was determined: (1) the RFLPs or SNPs PvuII and Xba1 in intron 1 of ER
(401 bp and 354 bp 5' of exon 2 respectively) and (2) the cSNP G229A in exon 1 of ER
with a missense mutation of Gly77Ser. These SNPs were then analyzed for an association with the statistically significant determined parameters concerning endometriosis.
| Materials and Methods |
|---|
|
|
|---|
Blood and tissue DNA isolation
From the 98 endometriosis and 98 control individuals genomic DNA isolation from peripheral blood was performed as previously described (Oppelt et al. 2005). Tissue samples were also analyzed from a portion of the endometriosis and control cohort. Genomic DNA was isolated from 42 of the 98 endometriosis lesions (AFS I (n = 2), AFS II (n = 4), AFS III (n = 8), AFS IV (n = 28)) and from 13 of the 98 normal patient-matched control tissues including endometrium (n = 5), peritoneum (n = 5), ovarian (n = 1), sacro-uterine ligament (n = 2). For tissue DNA isolation, 2050 mg frozen tissue were demembranated (Mikro-Dismembrator, B.Braun, Germany), then incubated overnight at 37 °C in a cell lysis buffer containing 1% SDS and proteinase K (Oppelt et al. 2005) and after a brief incubation with RNase A, the DNA was purified with phenol/chloroform, ethanol precipitated and quantitated. For all blood and tissue DNA samples an average of 70100 µg DNA per patient were isolated and stored at 80 °C.
Standard and real-time PCR, restriction enzyme digestion
A standard PCR reaction was performed using oligonucleotides and reaction specificities as described previously (Becherini et al. 2000). The PCR fragment was purified (PCR clean up kit; Qiagen, Hilden, Germany), digested to completion with PvuII or Xba1 (Roche, Mannheim, Germany) and then electrophoresed in 1% (w/v) agarose, ethidium bromide stained, photographed and analyzed. Genotypic allelic determination using RealTime PCR for the exonic DNA polymorphism G229A, which detects a G
A base change resulting in a non-synonymous amino acid change (Gly77Ser) in the transactivation domain at codon 77 of the ER
(refSNP ID: rs9340773) was designed using the PCR primers: 5' GCCAACGCGCAGGTCTA 3' and 5' CCCCAGGCCGTTGGA 3', and the allelic specific primers 5' TCAGACCGGCCTCC (VIC) and 5' TCAGACCAGCCTCC (FAM), then SNP analysis was performed using the ABI7000 according to the manufacturers instructions on the same patient DNA analyzed for PvuII and Xba1, as well as endometriotic lesions and control tissues. The ER
G229A SNP was quality control tested by Applied Biosystems (Applera, Darmstadt, Germany). Quality control was established in the laboratory by routine tests of DNA from the control collective with different SNP assays for homozygosity and heterozygosity.
| Results |
|---|
|
|
|---|
|
|
The PvuII, Xba1 and G229A SNPs in endometriosis and control individuals
Examining all allelic genotypes possible for the PvuII and Xba1 (pp, Pp, PP; xx, Xx, XX) polymorphisms, no general or specific statistically significant association was observed between both collectives and the above clinical parameters (Table 3
and data not shown). The AFS staging of the endometriotic lesions was also analyzed but this resulted in only a trend between individuals with the heterozygote Pp, homozygote XX alleles and AFS IV classification (Tables 4
and 5
). The G229A exonic SNP in the ER
transactivation domain has never previously been analyzed in the literature; therefore, we tested for any allelic segregation differences in blood DNA (98 controls + 98 patients) and tissue DNA from the same patients (47 lesions, 14 control tissues) in our collective groups. Our results showed that the SNP G229A was homozygote for GG at both alleles in all cases; therefore, at position 77 in the transactivation domain only glycine was present.
|
|
|
| Discussion |
|---|
|
|
|---|
gene. Stringent statistically significant associations compared with control individuals were observed with specific allergic responses and pain. Although no association of these parameters was observed with the ER
PvuII and/or Xba1 polymorphisms, a trend was noted with the endometriosis AFS IV classification (Table 5
Many SNPs also could represent spontaneous somatic mutations, which occur at higher rates in tumors (Jackson & Loeb 1998) or possibly in benign lesions. However, in both collective groups when DNA analysis was performed between blood, normal tissue and endometriosis lesions only the homozygote GG genotype for the exonic SNP G229A was detected. Although polymorphic in a North American population with an allele frequency of G/G (0.987) and A/G (0.013) (
2: 0.003) this exonic ER
SNP resulting in a non-synonymous Gly77Ser exchange, was not detected in our endometriosis and control collectives. Our total analyzed cohort of 196 individuals was homozygous wildtype for this SNP; therefore this SNP must be rare in the European population and irrelevant for the etiology of endometriosis.
Although endometriosis is a common gynecological disorder, the etiology is still poorly understood. Chronic pelvic inflammation with elevated cytokines is associated with endometriosis and the disease shares some similarities with autoimmune diseases (Nothnick 2001, Matarese et al. 2003). Earlier studies found a correlation between atopic diseases in 88 patients with endometriosis compared with 88 controls (Nichols et al. 1987). Using a more recent survey from the USA, Sinaii et al.(2002) investigated the relationship of concomitant diseases in 3680 endometriosis patients. Compared with published rates in the average USA female population, they found a higher rate of hypothyroidism, fibromyalgia, chronic fatigue syndrome, autoimmune diseases, allergies and asthma. Although this survey included a large patient cohort, the presence of a defined control collective, matched for age, race, as well as for demographic and epidemiological characteristics was lacking (Sinaii et al. 2002). In the present study, endometriosis patients had autoimmune diseases (n = 2), thyroid problems (n = 8) and chronic inflammations (n = 3), but none of these reached statistical significance when compared with the control group (Table 2
). No significant general difference between endometriosis patients and controls relating to allergies was found; however, endometriosis patients did show significantly more allergies against medicaments (P = 0.005) and pollen (P = 0.048) using the Students t-test, but only allergies against medicaments were statistically significant using the multivariate analysis (P = 0.042) (Table 2
). A positive link between first grade family history of allergies and endometriosis was also observed, supporting a genetic relationship. Two possibilities could explain the higher rate of allergies against medicaments: (1) an increased consumption of pain relieving medicaments and hormones, e.g. contraceptives or GnRH agonists, or (2) immunological problems. Several DNA polymorphisms of immune genes have been examined in lymphocytes for their association with endometriosis, including interleukin (IL)-1, -4, -6, -10 and tumor necrosis factor (TNF) alpha (reviewed in Wenzl et al. 2003). Only the IL-6 promoter polymorphism 174 G/C found in women of middle European origin could be involved in a predisposition to ovarian endometriosis with chocolate cysts (Wieser et al. 2003). It will be important to examine other gene polymorphisms which could be involved in allergies, for example the T-cell receptor gene. Interestingly, the presence of the ER together with estradiol was recently found to be essential for T cell lymphopoiesis and T cell-dependent inflammation (Islander et al. 2005). In this present study, no statistical association was noted between the SNPs of ER
gene and allergies in the patient and control groups, thus supporting the view that there is no role for the tested ER
polymorphism in a T-cell-dependent inflammatory response.
Although dysmenorrhea and subfertility problems are clearly associated with endometriosis, the molecular basis for subfertility is still unclear. Several molecular markers have been associated with the pathology of endometriosis and/or specifically with subfertility in these patients, including aromatase, endometrial bleeding associated-factor, hepatocyte growth factor, 17-HSD, HoxA10, A11, alpha(v), beta-3 integrin, leukemia inhibitory factor, matrix metalloproteases, and the estrogen and progesterone receptors (reviewed in Berube et al. 1998, Giudice & Kao 2004). In the present investigation, it was found that with both the Fishers exact and multivariate analyses dysmenorrhea was statistically significant (P = <0.001). In addition, the control group showed higher levels of positive pregnancies and positive live births compared with endometriosis patients, whereas endometriosis patients had more fertility problems. However, no positive association was found when compared with the PvuII and Xba1 SNPs in the ER
gene, supporting the view that there is no involvement with the above clinical phenotypes.
Endometriosis is an estrogen-dependent disease. It is possible that genetic variations in the estrogen-mediated pathway within the lesion could contribute to a more aberrant or increased estrogen effect promoting endometriosis initiation and invasion. When both PvuII and Xba1 polymorphisms were taken together, a trend for a higher risk for the more severe endometriosis (AFS IV) was found in the rarer genotypic (3 patients with endometriosis compared with 0 controls) subgroup, Xba1 (X/X) and PvuII (P/p) when compared with the non-severe endometriosis lesions (AFS IIII). The association of both the PvuII and Xba1 SNPs with diseases is extremely controversial: e.g. a positive correlation of PvuII was found in 188 tumor biopsies of breast cancer patients (Hill et al. 1989), but a negative correlation was determined in another analysis of 257 breast cancer patients and 140 peripheral blood DNA samples from healthy controls (Yaich et al. 1992). Similar controversial results were noted with a correlation of bone mineral density and endometriosis; for example, a positive correlation of the PvuII SNP and endometriosis was found in Japanese patients by Kitawaki et al.(2001), but no correlation of the PvuII and/or the Xba1 SNPs was observed in another Japanese study of endometriosis patients by Wang et al.(2004). In addition, no specific PvuII and/or Xba1 single genotype was noted when evaluated with AFS IV classification (Wang et al. 2004). In comparison with our study, it would be interesting to evaluate both the PvuII and the Xba1 SNPs in a multi-polymorphic analysis in association with AFS IV. So far, only one European study looking at a correlation between PvuII SNP and endometriosis has been performed a positive correlation with endometriosis was found in 57 Greek women (Georgiou et al. 1999). The present study involving German women represents the second European and Caucasian investigation, and we have investigated both the PvuII and XbaI SNPs, and a cSNP. Overall, some of the differences between these studies could be due to genotype-specific population differences (Japanese vs. Caucasian), multiple genotype analysis (PvuII alone or together with Xba1 or vice versa) or control group design. Defining a control group is problematic. This is, especially for endometriosis, ethically a difficult challenge, as healthy patients usually do not undergo diagnostic laparoscopy. The study by Kitawaki et al.(2001) involved 206 controls, consisting of a small group of 27 disease-free individuals (i.e. cervical cancer in situ, adhesions, tubal occlusions) and a diverse reference population of 179 elderly individuals chosen during an annual health examination. Patients with subfertility problems, adhesions or tubal occlusions are also often associated with endometriosis. Female newborns were the control collective in the study by Wang et al.(2004) and were defined as having a less than 2% lifetime risk of developing a severe endometriosis. The control cohort of the present study was age-matched, premenopausal with a regular menstruation cycle and no clinical signs of endometriosis or any abnormal pelvic pain. After 23 years, all control women were re-evaluated, and they still had no clinical signs of endometriosis or other symptoms relating to endometriosis.
Table 6
summarizes all of the literature regarding PvuII and Xba1 SNPs evaluated in endometriosis patients and in controls in different population groups. When both single and group combined percentages of all patients versus controls in single or combined analyses were studied, no significant differences were noted regarding the PvuII and Xba1 SNPs in Japanese, German or Greek population groups. This finding supports the view that these PvuII and Xba1 SNPs are not associated with endometriosis. More analysis should be performed in relation to the rarer multiple-SNP genotypes with AFS classification to reach a larger population size. It will be important to analyze other DNA polymorphisms associated with endometriosis in candidate genes involved in estrogen pathways. For example, the RsaI (exon 5) and AluI (exon 8) SNPs of the ERß gene in patients with endometriosis compared with controls showed no general association (Wang et al. 2004). However, a slight but statistically significant difference was observed between the frequency of the A allele in the AluI polymorphism and the AFS IV classification. In the future it will be important to determine genotyping and the functional roles of specific SNPs in molecular pathways involved in endometriosis.
|
| Acknowledgements |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Baranova H, Canis M, Ivaschenko T, Albuisson E, Bothorishvilli R, Baranov V, Malet P & Bruhat MA 1999 Possible involvement of arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 genes in the development of endometriosis. Molecular Human Reproduction 5 636641.
Becherini L, Gennari L, Masi L, Mansani R, Massart F, Morelli A, Falchetti A, Gonnelli S, Fiorelli G, Tanini A & Brandi ML 2000 Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Human Molecular Genetics 9 20432050.
Berube S, Marcoux S, Langevin M & Maheux R 1998 Fecundity of infertile women with minimal or mild endometriosis and women with unexplained infertility. The Canadian Collaborative Group on Endometriosis. Fertility and Sterility 69 10341041.[CrossRef][ISI][Medline]
Brodowska A 2003 The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes. Annales dAcademiae Medicae Stetinensis 49 111130.
Chang CC, Hsieh YY, Tsai FJ, Tsai CH, Tsai HD & Lin CC 2002 The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertility and Sterility 77 4345.[CrossRef][ISI][Medline]
Cramer DW, Hornstein MD, Ng WG & Barbieri RL 1996 Endometriosis associated with the N314D mutation of galactose-1-phosphate uridyl transferase (GALT). Molecular Human Reproduction 2 149152.[Medline]
Gazvani R & Templeton A 2002 New considerations for the pathogenesis of endometriosis. International Journal of Gynecology and Obstetrics 76 117126.[CrossRef]
Georgiou I, Syrrou M, Bouba I, Dalkalitsis N, Paschopoulos M, Navrozoglou I & Lolis D 1999 Association of estrogen receptor gene polymorphisms with endometriosis. Fertility and Sterility 72 164166.[CrossRef][ISI][Medline]
Giudice LC & Kao LC 2004 Endometriosis. Lancet 364 17891799.[CrossRef][ISI][Medline]
Hill SM, Fuqua SA, Chamness GC, Greene GL & McGuire WL 1989 Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Research 49 145148.
Hsieh YY, Chang CC, Tsai FJ, Wu JY, Tsai CH & Tsai HD 2001 Androgen receptor trinucleotide polymorphism in endometriosis. Fertility and Sterility 76 412413.[CrossRef][ISI][Medline]
Hu YF, Luscher B, Admon A, Mermod N & Tjian R 1990 Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes and Development 4 17411752.
Islander U, Erlandsson MC, Chavoshi T, Jochems C, Moverare S, Nilsson S, Ohlsson C, Gustafsson JA & Carlsten H 2005 Estren-mediated inhibition of T lymphopoiesis is estrogen receptor-independent whereas its suppression of T cell-mediated inflammation is estrogen receptor-dependent. Clinical and Experimental Immunology 139 210215.[CrossRef][ISI][Medline]
Jackson AL & Loeb LA 1998 The mutation rate and cancer. Genetics 148 14831490.
Jones RK, Bulmer JN & Searle RF 1995 Immunohistochemical characterization of proliferation, oestrogen receptor and progesterone receptor expression in endometriosis: comparison of eutopic and ectopic endometrium with normal cycling endometrium. Human Reproduction 10 32723279.
Kado N, Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Tsukamoto K, Hasegawa G, Nakamura N, Yoshikawa T & Honjo H 2002 Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Human Reproduction 17 897902.
Kashima K, Ishimaru T, Okamura H, Suginami H, Ikuma K, Murakami T, Iwashita M & Tanaka K 2004 Familial risk among Japanese patients with endometriosis. International Journal of Gynecology and Obstetrics 84 6164.[CrossRef]
Kitawaki J, Kusuki I, Koshiba H, Tsukamoto K, Fushiki S & Honjo H 1999 Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis. Fertility and Sterility 72 11001106.[CrossRef][ISI][Medline]
Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, Tsukamoto K, Hasegawa G, Nakamura N & Honjo H 2001 Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Human Reproduction 16 5155.
Kuohung W, Jones GL, Vitonis AF, Cramer DW, Kennedy SH, Thomas D & Hornstein MD 2002 Characteristics of patients with endometriosis in the United States and the United Kingdom. Fertility and Sterility 78 767772.[CrossRef][ISI][Medline]
Kurabayashi T, Matsushita H, Tomita M, Kato N, Kikuchi M, Nagata H, Honda A, Yahata T & Tanaka K 2004 Association of vitamin D and estrogen receptor gene polymorphism with the effects of long-term hormone replacement therapy on bone mineral density. Journal of Bone and Mineral Metabolism 22 241247.[CrossRef][ISI][Medline]
Lamb K & Nichols TR 1986 Endometriosis: a comparison of associated disease histories. American Journal of Preventative Medicine 2 324329.
Lessey BA, Metzger DA, Haney AF & McCarty KS Jr 1989 Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertility and Sterility 51 409415.[ISI][Medline]
Mahmood TA & Templeton A 1991 Prevalence and genesis of endometriosis. Human Reproduction 6 544549.
Mahutte NG, Matalliotakis IM, Goumenou AG, Koumantakis GE, Vassiliadis S & Arici A 2004 Elevations in peritoneal fluid macrophage migration inhibitory factor are independent of the depth of invasion or stage of endometriosis. Fertility and Sterility 82 97101.[ISI][Medline]
Marth G, Yeh R, Minton M, Donaldson R, Li Q, Duan S, Davenport R, Miller RD & Kwok PY 2001 Single-nucleotide polymorphisms in the public domain: how useful are they? Nature Genetics 27 371372.[CrossRef][ISI][Medline]
Matarese G, De Placido G, Nikas Y & Alviggi C 2003 Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? Trends in Molecular Medicine 9 223228.[CrossRef][ISI][Medline]
Matsuzaki S, Fukaya T, Uehara S, Murakami T, Sasano H & Yajima A 2000 Characterization of messenger RNA expression of estrogen receptor-alpha and -beta in patients with ovarian endometriosis. Fertility and Sterility 73 12191225.[CrossRef][ISI][Medline]
Meyer R 1919 Ueber den Stand der Frage der Adenomyositis und Adenomyome im allgemeinen und insbesondere ueber Adenomyositis seroepithelialis und Adenomyometritis sarcomatosa. Zentralblatt für Gynäkologie 36 745750.
Moen MH & Schei B 1997 Epidemiology of endometriosis in a Norwegian county. Acta Obstetrica et Gynecologica Scandinavica 76 559562.
Nichols TR, Lamb K & Arkins JA 1987 The association of atopic diseases with endometriosis. Annals of Allergy 59 360363.[ISI][Medline]
Noble LS, Simpson ER, Johns A & Bulun SE 1996 Aromatase expression in endometriosis. Journal of Clinical Endocrinology and Metabolism 81 174179.[Abstract]
Nothnick WB 2001 Treating endometriosis as an autoimmune disease. Fertility and Sterility 76 223231.[CrossRef][ISI][Medline]
Oppelt P, Strissel PL, Kellermann A, Seeber S, Humeny A, Beckmann MW & Strick R 2005 DNA sequence variations of the entire anti-Mullerian hormone (AMH) gene promoter and AMH protein expression in patients with the Mayer-Rokitanski-Kuster-Hauser syndrome. Human Reproduction 20 149157.
Parl FF, Cavener DR & Dupont WD 1989 Genomic DNA analysis of the estrogen receptor gene in breast cancer. Breast Cancer Research and Treatment 14 5764.[CrossRef][ISI][Medline]
Paul Dmowski W & Braun DP 2004 Immunology of endometriosis. Best Practice & Research in Clinical Obstetrics & Gynaecology 18 245263.[CrossRef][ISI]
Poppe K & Velkeniers B 2003 Thyroid disorders in infertile women. Annales dEndocrinologie 64 4550.
Sampson JA 1927 Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. American Journal of Obstetrics and Gynecology 14 442469.
Sano M, Inoue S, Hosoi T, Ouchi Y, Emi M, Shiraki M & Orimo H 1995 Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Biochemical and Biophysical Research Communications 217 378383.[CrossRef][ISI][Medline]
Seko M, Takeuchi H, Kinoshita K & Tokita A 2004 Association of bone mineral density with vitamin D and estrogen receptor gene polymorphisms during GnRH agonist treatment. Journal of Obstetrics Gynecology Research 30 130135.[CrossRef]
Sharpe-Timms KL 2001 Endometrial anomalies in women with endometriosis. Annals of the New York Academy of Sciences 943 131147.
Sharpe-Timms KL, Ricke EA, Piva M & Horowitz GM 2000 Differential expression and localization of de-novo synthesized endometriotic haptoglobin in endometrium and endometriotic lesions. Human Reproduction 15 21802185.
Simpson JL, Elias S, Malinak LR & Buttram VC Jr 1980 Heritable aspects of endometriosis. I. Genetic studies. American Journal of Obstetrics and Gynecology 137 327331.[ISI][Medline]
Sinaii N, Cleary SD, Ballweg ML, Nieman LK & Stratton P 2002 High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Human Reproduction 17 27152724.
Stefansson H, Geirsson RT, Steinthorsdottir V, Jonsson H, Manolescu A, Kong A, Ingadottir G, Gulcher J & Stefansson K 2002 Genetic factors contribute to the risk of developing endometriosis. Human Reproduction 17 555559.
Swiersz LM 2001 Role of endometriosis in cancer and tumor development. Annals of the New York Academy of Sciences 955 281292.[ISI]
Vigano P, Parazzini F, Somigliana E & Vercellini P 2004 Endometriosis: epidemiology and aetiological factors. Best Practice & Research in Clinical Obstetrics & Gynaecology 18 177200.[CrossRef][ISI]
Wang Z, Yoshida S, Negoro K, Kennedy S, Barlow D & Maruo T 2004 Polymorphisms in the estrogen receptor beta gene but not estrogen receptor alpha gene affect the risk of developing endometriosis in a Japanese population. Fertility and Sterility 81 16501656.[CrossRef][ISI][Medline]
Wenzl R, Kiesel L, Huber JC & Wieser F 2003 Endometriosis: a genetic disease. Drugs of Today 39 961972.[CrossRef][Medline]
Wieser F, Fabjani G, Tempfer C, Schneeberger C, Sator M, Huber J & Wenzl R 2003 Analysis of an interleukin-6 gene promoter polymorphism in women with endometriosis by pyrosequencing. Journal of the Society for Gynecological Investigation 10 3236.[CrossRef]
Witz CA & Burns WN 2002 Endometriosis and infertility: is there a cause and effect relationship? Gynaecologic and Obstetric Investigation 53 211.
Yaich L, Dupont WD, Cavener DR & Parl FF 1992 Analyzis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Research 52 7783.
Yamada Y, Ando F, Niino N, Ohta S & Shimokata H 2002 Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density of the femoral neck in elderly Japanese women. Journal of Molecular Medicine 80 452460.[CrossRef][ISI][Medline]
Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B & Bulun SE 1998 Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. Journal of Clinical Endocrinology and Metabolism 83 44744480.
Zhang ZL, Qin YJ, Huang QR, He JW, Li M, Zhou Q, Hu YQ & Li YJ 2004 Association of estrogen receptor-alpha and vitamin D receptor genotypes with therapeutic response to calcium in postmenopausal Chinese women. Acta Pharmacologica Sinica 25 16901697.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |